글로벌 시신경척수염 치료 시장 - 2028년까지의 산업 동향 및 예측

시장 분석 및 통찰력: 글로벌 시신경 척수염 치료 시장

시신경척수염 치료 시장은 2021년부터 2028년까지의 예측 기간 동안 5%의 시장 성장을 목격할 것으로 예상됩니다. Data Bridge Market Research의 시신경척수염 치료 시장 보고서는 예측 기간 내내 만연할 것으로 예상되는 다양한 요인에 대한 분석과 통찰력을 제공하고 시장 성장에 미치는 영향을 제공합니다. 전 세계적으로 염증성 질환의 유병률이 증가함에 따라 시신경척수염 치료 시장 성장이 가속화되고 있습니다.

시신경 척수염 스펙트럼 장애(NMOSD)는 척수와 시신경의 염증을 특징으로 하는 중추 신경계의 염증성 장애를 말합니다. 이 장애의 증상에는 마비, 근육 약화, 실명이 포함됩니다. 이는 백인이 아닌 여성에게 가장 흔한 것으로 알려져 있습니다.

전 세계적으로 시신경 척수염 스펙트럼 장애를 앓고 있는 사람들의 수가 증가하면서 시신경 척수염 치료 시장이 성장하는 주요 요인 중 하나가 되었습니다. 시신경 척수염 스펙트럼 장애 치료를 위한 신약 출시를 위한 협력이 증가하고, 민간 및 공공 기관에서 새로운 개입법을 개발하기 위한 연구자에게 재정 지원을 제공하면서 시장 성장이 가속화되었습니다. 마비 , 근력 약화, 실명 과 같은 합병증을 치료하기 위한 특정 약물 에 대한 수요가 증가 하고, 질병에 특화된 새로운 치료법에 대한 수요가 증가하면서 시장에 더 많은 영향을 미쳤습니다. 또한, 대규모 투자, 연구 개발 활동 증가, 인구 급증은 시신경 척수염 치료 시장에 긍정적인 영향을 미칩니다. 나아가, 치료법 개발과 신약 출시는 2021년에서 2028년까지의 예측 기간 동안 시장 참여자들에게 수익성 있는 기회를 확대합니다.

On the other hand, high cost associated with the neuromyelitis optica treatment is expected to obstruct the market growth. Lack of skilled expertise is projected to challenge the neuromyelitis optica treatment market in the forecast period of 2021-2028.

This primary haemophagocytic lymphohistiocytosis market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on primary haemophagocytic lymphohistiocytosis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth. 

Neuromyelitis Optica Treatment Market Scope and Market Size

The the neuromyelitis optica treatment market is segmented on the basis of type, treatment type, drugs, route of administration, and end-users. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of type, the neuromyelitis optica treatment market is segmented into neuromyelitis optica spectrum disorder with aquaporin-4 antibodies and neuromyelitis optica spectrum disorder without aquaporin-4 antibodies.
• On the basis of treatment type, the neuromyelitis optica treatment market is segmented into medication, plasma exchange therapy and immunoglobulin therapy.
• On the basis of drugs, the neuromyelitis optica treatment market is segmented into C5 protein inhibitor, oral corticosteroid, non-steroid immunosuppressive drugs and others.
• On the basis of route of administration, the neuromyelitis optica treatment market is segmented into oral and injectable.
• On the basis of end users, the neuromyelitis optica treatment market is segmented into hospitals, homecare, specialty clinics and others.

Global Neuromyelitis Optica Treatment Market Country Level Analysis

The neuromyelitis optica treatment market is analyzed and market size information is provided by country, type, treatment type, drugs, route of administration and end-users as referenced above.

The countries covered in the global neuromyelitis optica treatment market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

North America dominates the neuromyelitis optica treatment market due to the increase in awareness about diagnosis and new product launches within the region. Asia-Pacific is expected to witness high growth during the forecast period of 2021 to 2028 because of the increase in the patient pool in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

The neuromyelitis optica treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Neuromyelitis Optica Treatment Market Share Analysis

The neuromyelitis optica treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related neuromyelitis optica treatment market.

시신경척수염 치료 시장 보고서에서 다루는 주요 기업으로는 F. Hoffmann-La Roche Ltd, AstraZeneca, Teva Pharmaceutical Industries Ltd, Alexion Pharmaceuticals, Inc, Viela Bio, Anvil Biosciences, Opexa Therapeutics, Inc, Arrien Pharmaceuticals, LLC, TG Therapeutics, Inc, Bionure Farma, SL 등이 있으며, 국내 및 글로벌 기업도 있습니다. 시장 점유율 데이터는 글로벌, 북미, 유럽, 아시아 태평양(APAC), 중동 및 아프리카(MEA) 및 남미에 대해 별도로 제공됩니다. DBMR 분석가는 경쟁 우위를 이해하고 각 경쟁사에 대한 경쟁 분석을 별도로 제공합니다.

SKU-46311